The Allele Frequency of EGFR Mutations Predicts Survival in Advanced EGFR T790M-Positive Non-small Cell Lung Cancer Patients Treated with Osimertinib

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1776-260X
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
The Allele Frequency of EGFR Mutations Predicts Survival in Advanced EGFR T790M-Positive Non-small Cell Lung Cancer Patients Treated with Osimertinib ; day:3 ; month:12 ; year:2020 ; pages:1-8
Targeted oncology ; (3.12.2020), 1-8

Urheber
Buder, Anna
Hochmair, Maximilian J.
Filipits, Martin
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1007/s11523-020-00781-3
URN
urn:nbn:de:101:1-2021011218470924265752
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:32 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Buder, Anna
  • Hochmair, Maximilian J.
  • Filipits, Martin
  • SpringerLink (Online service)

Ähnliche Objekte (12)

EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients

EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance

ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer

ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis

Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors

Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors

Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC

Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC

Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung

Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung

Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer

Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer

Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation

Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation

Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs

Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs

Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib

Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib

Verbundene Objekte